#AbbVie

Stop me if you’ve heard this one before.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

This finding applies to those with Child-Pugh A cirrhosis who are treated with the Viekira regimen or Technivie, with or without ribavirin.

The two-drug regimen can cure the virus in as little as eight weeks.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

The evening dose of AbbVie’s hepatitis C treatment Viekira Pak may interact harmfully with HIV protease inhibitors.

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of...

The FDA has required AbbVie to change the labels for its two hepatitis C treatments after receiving numerous reports of serious liver...

In recent trials Harvoni, Viekira Pak and grazoprevir/elbasvir all cured high rates of hepatitis C among those coinfected with HIV.

The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among...